Atorvastatin treatment was associated with decreases of sICAM-1 ( from 274.2 + / -92.2 to 197.9 + / -70.0 ng/ml ; p < 0.01 ) and hsCRP ( from 0.57 + / -0.45 to 0.18 + / -0.15 mg/dl ; p < 0.01 ) , whereas placebo treatment had no effect on these markers .
